Furthermore, in vivo administration to Alzheimer’s disease mouse models resulted in better memory, reduced expression of inflammatory compounds (NF-κB, IL-6, IL-1β, and GFAP), and improved synaptic plasticity, mediated by synaptophysin. This evidence concerns the gene IL1B and early-onset autosomal dominant Alzheimer disease.